• 1
    Sadler JE. Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem 1998; 0: 395424.
  • 2
    Wagner DD. Cell biology of von Willebrand factor. Annu Rev Cell Biol 1990; 6: 21746.
  • 3
    Marti T, Rosselet SJ, Titani K, Walsh KA. Identification of disulfide-bridged substructures within human von Willebrand factor. Biochemistry 1987; 26: 8099109.
  • 4
    Sadler JE. A revised classification of von Willebrand disease. For the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 1994; 71: 5205.
  • 5
    Ginsburg D. Molecular genetics of von Willebrand disease. Thromb Haemost 1999; 82: 58591.
  • 6
    Eikenboom JC, Reitsma PH, Peerlinck KM, Briet E. Recessive inheritance of von Willebrand's disease type I. Lancet 1993; 341: 9826.
  • 7
    Eikenboom JC, Matsushita T, Reitsma PH, Tuley EA, Castaman G, Briet E, Sadler JE. Dominant type 1 von Willebrand disease caused by mutated cysteine residues in the D3 domain of von Willebrand factor. Blood 1996; 88: 243341.
  • 8
    Bodo I, Katsumi A, Tuley EA, Eikenboom JC, Dong Z, Sadler JE. Type 1 von Willebrand disease mutation Cys1149Arg causes intracellular retention and degradation of heterodimers: a possible general mechanism for dominant mutations of oligomeric proteins. Blood 2001; 98: 29739.
  • 9
    Goodeve AC, Eikenboom JC, Ginsburg D, Hilbert L, Mazurier C, Peake IR, Sadler JE, Rodeghiero F. A standard nomenclature for von Willebrand factor gene mutations and polymorphisms. On behalf of the ISTH SSC Subcommittee on von Willebrand factor. Thromb Haemost 2001; 85: 92931.
  • 10
    Voorberg J, Fontijn R, Calafat J, Janssen H, Van Mourik JA, Pannekoek H. Assembly and routing of von Willebrand factor variants: the requirements for disulfide-linked dimerization reside within the carboxy-terminal 151 amino acids. J Cell Biol 1991; 113: 195205.
  • 11
    Eikenboom JC, Castaman G, Vos HL, Bertina RM, Rodeghiero F. Characterization of the genetic defects in recessive type 1 and type 3 von Willebrand disease patients of Italian origin. Thromb Haemost 1998; 79: 70917.
  • 12
    Zhang ZP, Blombäck M, Egberg N, Falk G, Anvret M. Characterization of the von Willebrand factor gene (VWF) in von Willebrand disease type III patients from 24 families of Swedish and Finnish origin. Genomics 1994; 21: 18893.
  • 13
    Schneppenheim R, Budde U, Obser T, Brassard J, Mainusch K, Ruggeri ZM, Schneppenheim S, Schwaab R, Oldenburg J. Expression and characterization of von Willebrand factor dimerization defects in different types of von Willebrand disease. Blood 2001; 97: 205966.
  • 14
    Baronciani L, Cozzi G, Canciani MT, Peyvandi F, Srivastava A, Federici AB, Mannucci PM. Molecular characterization of a multiethnic group of 21 patients with type 3 von Willebrand disease. Thromb Haemost 2000; 84: 53640.
  • 15
    Montgomery RR, Jozwiak MA, Hutter JJ, Endres JL, Foster PA, Friedman D. A homozygous variant of von Willebrand Factor (VWF) that fails to C terminal dimerize resulting in loss of VWF multimers larger than dimer. Blood 1999; 94: 443a.
  • 16
    Burke RL, Pachl C, Quiroga M, Rosenberg S, Haigwood N, Nordfang O, Ezban M. The functional domains of coagulation factor VIII. C. J Biol Chem 1986; 261: 125748.
  • 17
    Wagner DD, Saffaripour S, Bonfanti R, Sadler JE, Cramer EM, Chapman B, Mayadas TN. Induction of specific storage organelles by von Willebrand factor propolypeptide. Cell 1991; 64: 40313.
  • 18
    DuBridge RB, Tang P, Hsia HC, Leong PM, Miller JH, Calos MP. Analysis of mutation in human cells by using an Epstein-Barr virus shuttle system. Mol Cell Biol 1987; 7: 37987.
  • 19
    Sambrook J, Fritsch EF, Maniatis T. Transfection of coprecipitates of calcium phosphate and DNA. In: Ford, N, Nolan, C, Ferguson, M, eds. Molecular Cloning: a Laboratory Manual. New York: Cold Spring. Harbor Laboratory Press, 1989: 16.3216.36.
  • 20
    Raines G, Aumann H, Sykes S, Street A. Multimeric analysis of von Willebrand factor by molecular sieving electrophoresis in sodium dodecyl sulphate agarose gel. Thromb Res 1990; 60: 20112.
  • 21
    Dong Z, Thoma RS, Crimmins DL, McCourt DW, Tuley EA, Sadler JE. Disulfide bonds required to assemble functional von Willebrand factor multimers. J Biol Chem 1994; 269: 67538.
  • 22
    Eikenboom JC. Congenital von Willebrand disease type 3: clinical manifestations, pathophysiology and molecular biology. Best Pract Res Clin Haematol 2001; 14: 36579.
  • 23
    Katsumi A, Tuley EA, Bodo I, Sadler JE. Localization of disulfide bonds in the cystine knot domain of human von Willebrand factor. J Biol Chem 2000; 275: 2558594.
  • 24
    Castaman G, Eikenboom JC, Lattuada A, Rodeghiero F. Grossly abnormal proteolysis of von Willebrand factor (VWF) in a patient heterozygous for a gene deletion and mutation in the dimerization area of VWF. Thromb Haemost 2000; 84: 72930.
  • 25
    Enayat MS, Guilliatt AM, Surdhar GK, Jenkins PV, Pasi KJ, Toh CH, Williams MD, Hill FG. Aberrant dimerization of von Willebrand factor as the result of mutations in the carboxy-terminal region: identification of 3 mutations in members of 3 different families with type 2A (phenotype IID) von Willebrand disease. Blood 2001; 98: 67480.
  • 26
    Schneppenheim R, Brassard J, Krey S, Budde U, Kunicki TJ, Holmberg L, Ware J, Ruggeri ZM. Defective dimerization of von Willebrand factor subunits due to a Cys[RIGHTWARDS ARROW]Arg mutation in type IID von Willebrand disease. Proc Natl Acad Sci USA 1996; 93: 35816.